BACKGROUND: In developing countries, malnutrition remains a common clinical syndrome at antiretroviral treatment (ART) initiation. Physiologic changes because of malnutrition and during nutritional recovery could affect the pharmacokinetics of antiretroviral drugs. METHODS:HIV-infected children admitted with severe acute malnutrition were randomized to early or delayed initiation of lopinavir (LPV)/ritonavir, abacavir and lamivudine using World Health Organization weight band dosage charts. LPV concentrations were measured on day 1 and day 14. Thereafter, patients were followed-up to week 48. The population pharmacokinetics of LPV was described using NONMEM v7.3. Covariates were screened to assess their influence on the pharmacokinetics of LPV, and the relationship between pharmacokinetic variability and treatment outcomes were assessed. RESULTS:Five hundred and two LPV concentrations were collected from 62 pediatric patients 0.1-3.9 years of age (median: 0.9 years). Rifampin-based antituberculosis treatment and "super-boosted" LPV/ritonavir were prescribed in 20 patients. LPV disposition was well described by a one-compartment model with first-order elimination. Neither randomization to early or delayed ART, tuberculosis comedications nor anthropometrical measurements explained the pharmcokinetic variability. Allometrically scaled fat-free mass influenced apparent clearance (CL/F) and volume of distribution (Vd/F). Pharmacokinetic exposure did not correlate with virologic outcomes or death at 12 or 48 weeks. CONCLUSIONS:LPV pharmacokinetics was influenced by fat-free mass and not by timing of ART initiation or tuberculosis comedication in severely malnourished HIV-infected children. LPV pharmacokinetics was found to be highly variable and bioavailability greatly reduced, resulting in a high CL estimate in this population. The role of LPV dose adjustment should be further evaluated in severely malnourished children initiating ART.
RCT Entities:
BACKGROUND: In developing countries, malnutrition remains a common clinical syndrome at antiretroviral treatment (ART) initiation. Physiologic changes because of malnutrition and during nutritional recovery could affect the pharmacokinetics of antiretroviral drugs. METHODS:HIV-infectedchildren admitted with severe acute malnutrition were randomized to early or delayed initiation of lopinavir (LPV)/ritonavir, abacavir and lamivudine using World Health Organization weight band dosage charts. LPV concentrations were measured on day 1 and day 14. Thereafter, patients were followed-up to week 48. The population pharmacokinetics of LPV was described using NONMEM v7.3. Covariates were screened to assess their influence on the pharmacokinetics of LPV, and the relationship between pharmacokinetic variability and treatment outcomes were assessed. RESULTS: Five hundred and two LPV concentrations were collected from 62 pediatric patients 0.1-3.9 years of age (median: 0.9 years). Rifampin-based antituberculosis treatment and "super-boosted" LPV/ritonavir were prescribed in 20 patients. LPV disposition was well described by a one-compartment model with first-order elimination. Neither randomization to early or delayed ART, tuberculosis comedications nor anthropometrical measurements explained the pharmcokinetic variability. Allometrically scaled fat-free mass influenced apparent clearance (CL/F) and volume of distribution (Vd/F). Pharmacokinetic exposure did not correlate with virologic outcomes or death at 12 or 48 weeks. CONCLUSIONS:LPV pharmacokinetics was influenced by fat-free mass and not by timing of ART initiation or tuberculosis comedication in severely malnourished HIV-infectedchildren. LPV pharmacokinetics was found to be highly variable and bioavailability greatly reduced, resulting in a high CL estimate in this population. The role of LPV dose adjustment should be further evaluated in severely malnourished children initiating ART.
Authors: K M L Crommentuyn; B S Kappelhoff; J W Mulder; A T A Mairuhu; E C M van Gorp; P L Meenhorst; A D R Huitema; J H Beijnen Journal: Br J Clin Pharmacol Date: 2005-10 Impact factor: 4.335
Authors: Louisa Pollock; Laura Else; Goenke Poerksen; Elizabeth Molyneux; Peter Moons; Sarah Walker; William Fraser; David Back; Saye Khoo Journal: J Antimicrob Chemother Date: 2009-10-06 Impact factor: 5.790
Authors: Diane E T Bastiaans; Silvia Forcat; Hermione Lyall; Tim R Cressey; Rawiwan Hansudewechakul; Suparat Kanjanavanit; Antoni Noguera-Julian; Christoph Königs; Jamie R J Inshaw; Suwalai Chalermpantmetagul; Yacine Saïdi; Alexandra Compagnucci; Lynda M Harper; Carlo Giaquinto; Angela P H Colbers; David M Burger Journal: Pediatr Infect Dis J Date: 2014-03 Impact factor: 2.129
Authors: Aaloke Mody; Sarah Bartz; Christoph P Hornik; Tonny Kiyimba; James Bain; Michael Muehlbauer; Elizabeth Kiboneka; Robert Stevens; John V St Peter; Christopher B Newgard; John Bartlett; Michael Freemark Journal: PLoS One Date: 2014-07-22 Impact factor: 3.240
Authors: Tjokosela Tikiso; Helen McIlleron; David Burger; Diana Gibb; Helena Rabie; Janice Lee; Marc Lallemant; Mark F Cotton; Moherndran Archary; Stefanie Hennig; Paolo Denti Journal: Br J Clin Pharmacol Date: 2021-08-12 Impact factor: 3.716
Authors: Tom G Jacobs; Elin M Svensson; Victor Musiime; Pablo Rojo; Kelly E Dooley; Helen McIlleron; Rob E Aarnoutse; David M Burger; Anna Turkova; Angela Colbers Journal: J Antimicrob Chemother Date: 2020-12-01 Impact factor: 5.790
Authors: Luka Verrest; Erica A Wilthagen; Jos H Beijnen; Alwin D R Huitema; Thomas P C Dorlo Journal: Clin Pharmacokinet Date: 2021-06-01 Impact factor: 5.577